Literature DB >> 7576703

CFTR-mediated chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells.

T J Kelley1, L al-Nakkash, M L Drumm.   

Abstract

Chloride channel activity of cystic fibrosis transmembrane conductance regulator (CFTR) requires activation of protein kinase A (PKA) by 3'-5'-cyclic adenosine monophosphate (cAMP). The level of cAMP is controlled by the balance between cAMP synthesis and hydrolysis by adenylate cyclase and phosphodiesterases (PDEs), respectively. CFTR channel activity appears to be most sensitive to the activity of type III cyclic nucleotide PDEs in Calu-3 and 16HBE cells, both derived from airway epithelium and expressing wild-type CFTR. Type III PDEs can be identified by their sensitivity to specific inhibitors such as milrinone and amrinone. In Calu-3 cells, specific inhibition of type III PDEs increased chloride efflux up to 13.7-fold, whereas neither rolipram nor Ro20-1724 (type IV PDE inhibitors) nor 3-isobutyl-1-methylxanthine (IBMX, a nonspecific PDE inhibitor) elicited significant increases. None of these compounds had an appreciable effect on total cellular cAMP levels, yet the effects of milrinone and amrinone on chloride efflux were blocked by treatment of cells with Rp-cAMPS, a cAMP analog that inhibits PKA at the site of cAMP binding. Similarly, H-8, an inhibitor of PKA, reduced milrinone-stimulated chloride efflux, indicating that efflux is mediated through the cAMP/PKA pathway. Whole-cell patch clamp analysis revealed that milrinone generated chloride conductances with properties consistent with those of CFTR. Milrinone elicited chloride currents in a dose-dependent manner and induced CFTR activity in the absence of adenylate cyclase agonists. These data suggest that type III PDEs are specifically involved in CFTR activation in airway epithelial cells and that PDE regulation of CFTR may involve subcellular compartments of cAMP.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7576703     DOI: 10.1165/ajrcmb.13.6.7576703

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  12 in total

1.  Anchored PDE4 regulates chloride conductance in wild-type and ΔF508-CFTR human airway epithelia.

Authors:  Elise Blanchard; Lorna Zlock; Anna Lao; Delphine Mika; Wan Namkung; Moses Xie; Colleen Scheitrum; Dieter C Gruenert; Alan S Verkman; Walter E Finkbeiner; Marco Conti; Wito Richter
Journal:  FASEB J       Date:  2013-11-07       Impact factor: 5.191

2.  Activation of endogenous deltaF508 cystic fibrosis transmembrane conductance regulator by phosphodiesterase inhibition.

Authors:  T J Kelley; L Al-Nakkash; C U Cotton; M L Drumm
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

Review 3.  Cystic fibrosis transmembrane regulator protein mutations: 'class' opportunity for novel drug innovation.

Authors:  Kelvin D MacDonald; Karen R McKenzie; Pamela L Zeitlin
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

4.  In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium.

Authors:  T J Kelley; K Thomas; L J Milgram; M L Drumm
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

5.  The regulation of lung liquid absorption by endogenous cAMP in postnatal sheep lungs perfused in situ.

Authors:  R H Stephens; A R Benjamin; D V Walters
Journal:  J Physiol       Date:  1998-09-01       Impact factor: 5.182

Review 6.  Mechanisms of bicarbonate secretion: lessons from the airways.

Authors:  Robert J Bridges
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

7.  Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004.

Authors:  R Dérand; L Bulteau-Pignoux; F Becq
Journal:  J Membr Biol       Date:  2003-07-15       Impact factor: 1.843

Review 8.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

10.  Compartmentalized cyclic adenosine 3',5'-monophosphate at the plasma membrane clusters PDE3A and cystic fibrosis transmembrane conductance regulator into microdomains.

Authors:  Himabindu Penmatsa; Weiqiang Zhang; Sunitha Yarlagadda; Chunying Li; Veronica G Conoley; Junming Yue; Suleiman W Bahouth; Randal K Buddington; Guangping Zhang; Deborah J Nelson; Monal D Sonecha; Vincent Manganiello; Jeffrey J Wine; Anjaparavanda P Naren
Journal:  Mol Biol Cell       Date:  2010-01-20       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.